ATLANTA, Aug. 9, 2013 /PRNewswire/ -- With a score of 93.1 out of 100, Elekta's Leksell Gamma Knife® Perfexion system earned the top ranking, receiving high marks for uptime, treatment times and planning speeds, according to KLAS research firm's recently released customer survey, Radiation Therapy 2013: Striving for Accuracy and Upgradeability*. Elekta Infinity radiation treatment system received the #2 ranking with a score of 87.8.
The 2013 KLAS report based on interviews with 169 U.S. providers states that "[Elekta] field service engineers are very available and perform effective preventive maintenance, as is evidenced by [the Perfexion system's] extremely high uptime rates." The report quotes a chief physicist respondent as saying "Leksell Gamma Knife Perfexion never has downtime. That is partly because of the almost obsessive preventive maintenance done by Elekta. The Perfexion team is really here for us."
The report also cites the rapid treatment times for patients and planning speed: "Perfexion users are very vocal about the precise treatment that works incredibly well for treating brain tumors. Because of the accuracy, the healthy tissue is not affected."
Elekta Infinity earned high scores for reliability in the study, which states that "providers say that the excellent field support helps with the uptime, and fantastic field support is also one thing that differentiates Elekta from other vendors." A physicist surveyed about Elekta field service people says: "They are the best I have ever had in the fieldthe Elekta people are just way above and beyond."
The report also cites ease of use of Elekta Infinity as a positive aspect, specifically the automated features and computerization of many functions.
Although it was below the threshold for ranking with four respondents, Elekta's Agility 160-leaf multileaf collimator (MLC) received high praise, according to the report. One of those surveyed says: "Elekta's new MLC is really the next big thing in oncology."
Agility is standard equipment on Elekta's new Versa HD system. The high-definition Agility beam shaping and High Dose Rate mode in Versa HD give clinicians the flexibility to deliver conventional therapies to treat a wide range of small and large tumors throughout the body, while also enabling treatment of highly complex cancers that require extreme targeting precision.
*Radiation Therapy 2013: Striving for Accuracy and Upgradeability,© July, 2013, KLAS Enterprises, LLC. All rights reserved. www.KLASresearch.com
Elekta Infinity and Versa HD are not for sale or distribution in all markets.
For further information, please contact:
Johan Andersson, Director, Investor Relations, Elekta AB
Tel: +46 702 100 451, email: firstname.lastname@example.org
Time zone: CET: Central European Time
Michelle Joiner, Director, Global Public Relations and Brand Management, Elekta
Tel: +1 770-670-2447, email: email@example.com
Time zone: ET: Eastern Time
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,500 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. Website: www.elekta.com.
KLAS is a research firm on a global mission to improve healthcare delivery by enabling providers to be heard and to be counted. Working with thousands of healthcare executives and clinicians, KLAS gathers data on software, services, medical equipment, and infrastructure systems to deliver timely reports, trends, and statistical overviews. The research directly represents the provider voice and acts as a catalyst for improving vendor performance. KLAS was founded in 1996, and their staff and advisory board members average 25 years of healthcare information technology experience. For more information, go to www.KLASresearch.com, email marketing@KLASresearch.com, or call 1-800-920-4109 to speak with a KLAS representative. Follow KLAS on Twitter @KLASresearch.